Invited Commentary
- PMID: 38517076
- DOI: 10.1097/XCS.0000000000001085
Invited Commentary
References
-
- McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148–158.
-
- Chen JY, Pan HC, Shiao CC, et al. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Cardiovasc Diabetol. 2023;22:290.
-
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145:e895–e1032.
-
- Filippatos TD, Liontos A, Papakitsou I, Elisaf MS. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgrad Med. 2019;131:82–88.
-
- Harris DD, Sabe SA, Broadwin M, et al. Proteomic analysis and sex-specific changes in chronically ischemic swine myocardium treated with sodium-glucose cotransporter-2 inhibitor canagliflozin. J Am Coll Surg. 2024;238:1045–1055.
LinkOut - more resources
Full Text Sources
